Intellia Therapeutics Inc (NTLA)
SG&A Expense Growth
-4.79%
Fiscal year · Period ending:
NTLA SG&A Expense Growth
Latest reported-4.79%period ending
Latest reported-4.79%period ending
NTLA FY SG&A Growth (YoY) (0.00% → -4.79%)
Latest values, visible window
High-resolution chart · PNG
NTLA sg&a expense growth history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | SG&A Expense Growth |
|---|---|
| -4.7914% | |
| 8.0105% | |
| 29.0025% | |
| 27.0198% | |
| 60.9636% | |
| 7.5771% | |
| 27.5529% | |
| 14.8582% | |
| 66.8353% | |
| 102.8009% | |
| 132.1143% | |
| 0% |